Tyck till om SwePub Sök här!
onr:"swepub:oai:DiVA.org:uu-2709"
Search: onr:"swepub:oai:DiVA.org:uu-2709" > Current Medical Tre...
- 1 of 1
- Previous record
- Next record
- To hitlist
Current Medical Treatment of Endocrine Pancreatic Tumors and Future Aspects
-
- Fjällskog, Marie-Louise (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Vatn, Morten, Ph.D (opponent)
- Med avd Gastro, Rikshospitalet, Oslo
- (creator_code:org_t)
- ISBN 9155454240
- Uppsala : Acta Universitatis Upsaliensis, 2002
- English 71 s.
- Series: Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 0282-7476 ; 1191
- Doctoral thesis (other academic/artistic)
Abstract
Subject headings
Close
- We treated 16 patients with somatostatin analogs combined with α-interferon and achieved a biochemical and/or radiological response in 56% (median duration 22 months). We consider this treatment a good alternative for patients who fail during chemotherapy or who do not want to/cannot receive cytotoxic drugs.Thirty-six patients with neuroendocrine tumors were treated with cisplatin combined with etoposide. Of 14 patients with evaluable EPTs, 50% responded radiologically and/or biochemically (median duration 9 months). We consider this treatment useful as first-line medical treatment in aggressive EPTs or in patients failing prior chemotherapy.Twenty-eight tumor tissues from EPTs were examined with immunohistochemistry regarding expression of somatostatin receptors (ssts) 1 to 5 on tumor cells and in intratumoral vessels. We found that sst2 and sst4 were highly expressed on tumor cells and in vessels. However, sst3 and sst5 were lacking in half of the tumor tissues and in most of the vessels. Because of the variability in sst expression, we recommend analysis of each individual’s receptor expression before starting treatment.Endocrine pancreatic tumors (EPTs) are rare with an incidence of 4 per million inhabitants. In the majority of cases they grow slowly, but there are exceptions with very rapidly progressing malignant carcinomas. First-line medical treatment is streptozotocin combined with 5-fluorouracil.We examined 38 tumor samples regarding expression of tyrosine kinase receptors platelet-derived growth factor receptors (PDGFRs), c-kit and epidermal growth factor receptor (EGFR). We found that the receptors were expressed in more than half of the tumor tissues. Further studies will reveal if tyrosin kinase antagonists can be part of the future treatment arsenal.
Keyword
- Medical sciences
- pancreatic tumors
- somatostatin analogs
- cisplatin
- etoposide
- somatostatin receptors
- immunohistochemistry
- tyrosine kinase receptors
- platelet-derived growth factors receptors (PDGFRs)
- c-kit
- epidermal growth factor receptor (EGFR)
- MEDICIN OCH VÅRD
- alfa-interferon
- MEDICINE
- MEDICIN
- Medicine
- medicin
Publication and Content Type
- vet (subject category)
- dok (subject category)
Find in a library
- Current Medical Treatment of Endocrine Pancreatic Tumors and Future Aspects (Search the publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Fjällskog, Marie ...
- Vatn, Morten, Ph ...
- Parts in the series
- Comprehensive Su ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
